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Background: Post-Soviet Kyrgyzstan has experienced a major surge in blood-borne infections, but data from adequately
powered, up-to-date studies are lacking. We thus examined a) the seroprevalences of hepatitis B virus surface antigen
(HBsAg), HIV-1 p24 antigen and antibodies against hepatitis C virus (anti-HCV), human immunodeficiency viruses
(anti-HIV-1/2, HIV-1 group O), and Treponema pallidum among blood donors in Kyrgyzstan and assess their
distribution according to sex, age, and provinces of residence; b) trends in the respective seroprevalences; and c)
co-infection rates among the pathogens studied.
Methods: Serological screening was performed on 37 165 blood donors at the Republican Blood Centre in Bishkek,
Kyrgyzstan, between January 2013 and December 2015. We applied poststratification weights to control for sampling
bias and used logistic regression analyses to examine the association of seropositivity and co-infections with sex, age,
provinces of residence, and year of blood donation.
Results: Twenty nine thousand and one hundred forty-five (78%) donors were males and 8 020 (22%) were females.
The median age was 27 years (range: 18 – 64). The prevalences of HBsAg, anti-HCV, HIV (p24 Ag and anti-HIV), and
anti-T. pallidum were 3.6% (95%CI: 3.4 – 3.8%), 3.1% (3.0 – 3.3%), 0.78% (0.69 – 0.87%), and 3.3% (3.1 – 3.5%),
respectively. Males were more likely to be seropositive for HBsAg than females (OR: 1.63; 95%CI: 1.40 – 1.90), but less
likely to be seropositive for anti-HCV (0.85; 0.74 – 0.98) and HIV (0.65; 0.49 – 0.85). Prevalences were lower in the capital
than in the other provinces. There was a decreasing trend in the seroprevalences of HBsAg, anti-HCV, and anti-T.
pallidum from 2012 to 2015 (P-value for trend, P = 0.01, P < 0.0001, P < 0.0001, respectively), while the seroprevalence of
HIV increased (P = 0.049). One hundred eighty donors (0.48%) were seropositive for multiple infections. The highest
co-infection rate was observed between anti-T. pallidum and HBsAg (6.0%), followed by anti-HCV and anti-T. pallidum
(5.2%), and HIV and anti-HCV (4.9%).
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Conclusions: The data suggest that Kyrgyzstan can be reclassified from high to lower-intermediate HBsAg endemicity,
whereas the high HIV prevalence with a rising trend is an alarming finding that needs to be urgently addressed by
public health authorities. The observed co-infections suggest common risk factors but also common preventive
interventions.
Keywords: Hepatitis B, Hepatitis C, Human immunodeficiency virus, T. pallidum, Co-infections, Prevalence, Blood
donors, KyrgyzstanMultilingual abstracts
Please see Additional file 1 for translation of the abstract
into the five official working languages of the United
Nations.Background
Hepatitis B virus (HBV), hepatitis C virus (HCV), human
immunodeficiency virus (HIV), and Treponema pallidum
still cause high burdens of disease in many countries, es-
pecially in developing countries. For example, 184 million
and 248 million individuals worldwide are chronic carriers
of HCV and HBV, respectively [1, 2]. In addition, around
six million individuals are infected with T. pallidum [3]
and 37 million individuals are living with HIV/acquired
immunodeficiency syndrome (AIDS) globally [4].
The transmission of these infectious agents comprises
various routes, including transmission from mother to in-
fant (vertical transmission), sexual transmission, exposure
to infected blood due to using contaminated needles and
syringes, and the transfusion of infected blood or its
components. The latter route is very important since a
blood transfusion is a frequent therapeutic procedure,
with around 108 million units of donated blood collected
every year worldwide [5]. Thus, the World Health
Organization (WHO) recommends that all blood dona-
tions should be screened for selected infections prior to
use and that screening should be mandatory for HBV,
HCV, HIV, and T. pallidum [5]. Evaluation of data on the
prevalence of these infections among blood donors may
provide information about the epidemiology of these
infections in the general population [1, 6].
Kyrgyzstan is one of the 15 former Soviet republics
that became independent in 1991 after the collapse of
the Soviet Union. Since then, the country has experi-
enced a deep political, economic, and societal crisis,
which has resulted in deteriorating health among the
population, including increased morbidity and mortality
due to infectious diseases [7, 8]. Kyrgyzstan is classified
as a lower middle-income country with around one third
of the population living below the poverty line.
Up until now, only a few studies have assessed the preva-
lences of infectious diseases in Kyrgyzstan. Most of them
have been conducted in selected subpopulations or featured
small sample sizes; for infections such as syphilis there areno up-to-date data at all. The recently published data on
global prevalence of chronic HBV classified Kyrgyzstan as a
country with high endemicity [1]. However, this classifica-
tion was based on a single publication from 1992 [9]. The
prevalences of HIV in the general Kyrgyz population seem
to be low; however, we are not aware of any study that has
assessed the prevalence of HIV in the general population or
among blood donors.
It is estimated that the prevalence of HIV in adults is
around 0.1% in Kyrgyzstan [10]. Kyrgyzstan is one of the
countries with the fastest growing HIV epidemics along
with Ukraine, Russia, and Uzbekistan. Regarding HCV,
Kyrgyzstan was classified as a country with a high preva-
lence (>3.5%) in 2005 [2]. After the breakdown of the Soviet
Union, the incidence of syphilis increased dramatically in
most former Soviet republics including Kyrgyzstan [11]. It
began to decline in 1997 but current data are lacking.
In addition, little is known about co-infection rates of
the abovementioned infections in Kyrgyzstan. This infor-
mation is important to have, as co-infections may lead to
more severe disease outcomes and faster disease progres-
sion. For example, HIV infection may accelerate the
course of HBV and HCV infection by leading to faster
development of fibrosis and cirrhosis [12, 13]. Treatment
of co-infections can also be problematic as it is associated
with an increased risk of side effects due to drug-drug in-
teractions and poor compliance if treatment is aborted
early, as in the case of HIV/HCV treatment [14]. Lastly,
recognition of co-infections is important because shared
transmission routes and mechanisms may suggest com-
mon preventive interventions.
With all this in mind, the aims of the present study were
to a) examine the seroprevalences of hepatitis B surface
antigen (HBsAg), antibodies against HCV and T. pallidum,
and HIV-1 p24 antigen plus anti-HIV antibodies among
blood donors in Kyrgyzstan according to sex, age, and
provinces of residence; b) examine trends in the respective
seroprevalences over time; and c) assess co-infection rates
among the pathogens studied.Methods
Sampling
We used data of 37 165 adult volunteers who donated blood
at the Republican Blood Centre in Bishkek, Kyrgyzstan
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former Soviet republic located in Central Asia. The popula-
tion was approximately 5,940,000 in 2015 [15].
Physicians interviewed the potential donors before the
blood donation. A physician collected information on the
presence of acute and chronic infectious diseases, chronic
noncommunicable diseases, and risk factors for blood-
transmissible diseases (e.g., men who have sex with men
[MSM] or sex workers) during face-to-face interviews. In
addition, height, weight, blood pressure, and body
temperature were measured. Only individuals without a
history of the abovementioned diseases or risk factors for
blood-transmissible diseases were allowed to donate
blood. There were no financial or other incentives for
blood donation. In the case of serial blood donations
during the study period, we only included one randomly
selected serological result.
Laboratory analysis
Enzyme-linked immunoassay (ELISA) tests were per-
formed using a microplate spectrophotometer (Thermo
Scientific Multiskan FC, Vantaa, Finland). The kits DS-
EIA-HBsAg, EIA anti-HCV, DS-EIA-HIV-AgAb-SCREEN,
and EIA-anti-LUES-GM manufactured by RPC Diagnostic
systems (Nizhny Novgorod, Russia) were used to test for
the presence of HBsAg, and HIV-1 p24 antigen; and for
antibodies against HCV (anti-HCV, for HCV core antigen,
NS3Ag, NS4Ag, and NS5-Ag) and HIV (anti-HIV-1/2,
HIV-1 group O); and T. pallidum (anti-T. pallidum), re-
spectively. Seropositivity for HIV was defined as detection
of HIV-1 p24 antigen and/or anti-HIV antibodies, as the
read-out from the HIV test can come from reactivity with
either p24 Ag or anti-HIV antibodies. All positive samples
were retested once using the same ELISA assays and the
same blood sample.
Samples were considered positive if results were posi-
tive in both tests. Overall, the ELISA tests used have
high sensitivity and specificity (see Table 1) and have
been licensed for use by the Kyrgyzstan Ministry of
Health.
Statistical analysis
Since the proportion of male and younger donors was
higher in the sample than in the general population, we
applied poststratification weights using sex and 10-yearTable 1 ELISA kits used in the study
Kit names Infection Sensitivity Specificity
DS-EIA-HBsAg HBV 100% 99%
EIA anti-HCV HCV 100% 100%
DS-EIA-HIV-AgAb-SCREEN HIV 100% 99.6%
EIA-anti-LUES-GM Syphilis 99.4% 99.6%
aNumerically not quantified, but significantly below the optical density correspondiage groups. The sex and age distribution of the Kyrgyz
population was taken from the last census conducted in
2009 [16]. We then calculated weighted sex- and age-
specific prevalence rates of HBV, HCV, HIV, and T.
pallidum. Furthermore, we used linear-by-linear associ-
ation from the chi-square test to examine trends in the
seroprevalence rates. As a next step, we applied logistic
regression analysis to examine odds of seropositivity by
adjusting for donors’ sex, age, province of residence, and
year of blood donation.
Four separate models (HBV, HCV, HIV, and T. pallidum)
were created. A separate logistic regression model was cre-
ated to examine the odds of having co-infections, adjusting
for sex, age, province of residence, and year of blood dona-
tion. Finally, we examined the effects of co-infections on
the respective seropositivities using a logistic regression
model with, for example, HBV as a dependent and T.
pallidum as an independent variable or vice versa, and
adjusted for sex and age.
Analyses were performed with IBM SPSS Statistics for
Windows, version 19 (IBM Corporation, Armonk, NY,
USA). The Venn diagram (see Fig. 2) was drawn using
the package ‘VennDiagram’ in the R Foundation for Stat-
istical Computing, version 3.0.2.
Results
Of the 37 165 blood donors, 29 145 (78%) were males
and 8 020 (22%) were females. The median age was
27 years (range: 18 – 64). More than half (54%) were
from the age group ‘20–29 years’. Almost half of the
donors (49%) lived in the capital, Bishkek (see Table 2).
The prevalences of HBsAg, anti-HCV, HIV, and anti-T.
pallidum were 3.6% (95%CI: 3.4 – 3.8%), 3.1% (3.0 – 3.3%),
0.78% (0.69 – 0.87%), and 3.3% (3.1 – 3.5%), respectively.
Males were more likely to be seropositive for HBsAg in all
age groups, while females were more likely to be seroposi-
tive for anti-HCV and HIV (see Fig. 1, and Table 3). The
odds of seropositivity for HBsAg and anti-HCV increased
with age (see Fig. 1). The highest odds of seropositivity for
T. pallidum were observed in the age group ‘40-49 years’
and decreased in later years. Regional differences in sero-
prevalences were also observed: for most infections, they
were lower in the capital than in the other provinces (see
Table 3). There was a decreasing trend with time in the ser-
oprevalences of HBsAg (P for trend, P = 0.01), anti-HCVDetection limits Manufacturer’s catalogue number Reference
0.05 IU/ml B-1154 [37]
NQa C-153 [38]
0.05 IU/ml I-1654 [39]
0.0047 IU/ml L-155 [40]
ng to the definition of a positive test
Table 2 Descriptive characteristics of the study population
Characteristics Unweighted (n) Percent (%)
Sex
Male 29 145 78.4
Female 8 020 21.6
Median age in years (range, IQR) 27 (18 – 64; 22 – 36)
Age group
< 20 years 1 679 4.0
20 – 29 years 20 213 54.4
30 – 39 years 8 547 23.0
40 – 49 years 4 457 12.0
50 – 59 years 2 278 6.1
> 60 years 191 0.5
Province of residence
Bishkek (capital) 18 086 48.7
Chuy province 10 786 29.0
Issyk-Kul province 2 574 6.9
Talas province 961 2.6
Naryn province 2 050 5.5
Jalal-Abad province 1 305 3.5
Osh province 784 2.1
Batken province 614 1.7
Foreign country 4 0.01
Year of blood donation
2013 12 086 32.5
2014 12 437 33.5
2015 12 642 34.0
Total 37 165 100
IQR interquartile range
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prevalence of HIV was higher in 2014 and 2015 than in
2013 (P for trend, P = 0.049).
The co-infection rates for HBV, HCV, HIV, and T. pal-
lidum are presented in Table 4. The highest co-infection
rate was observed between T. pallidum and HBV (6.0%),
followed by HCV and T. pallidum (5.2%), and HIV and
HCV (4.9%).
The risks of HBV and HCV seropositivity were signifi-
cantly higher among blood donors who were also seroposi-
tive for T. pallidum. The risk of acquiring HCV
seropositivity was 1.83 times higher for donors positive for
HIV infection (see Table 5). In total, 180 (0.48%) blood do-
nors were found to be seropositive for more than one infec-
tion (see Fig. 2). One person (male, age group 30 – 39 years)
was positive for three infections: HBV, HIV, and T. pallidum.
In five individuals (all males between 39 and 56 years of age),
results were positive for HBV, HCV, and T. pallidum.
Results of multivariable logistic regression analyses
showed that male sex (adjusted odds ratio, AOR: 1.64;95% confidence intervals, CIs: 1.09 – 2.48), older age,
and residing in Osh province (OR: 2.19, 95%CI: 1.05
– 4.59) were positively associated with having co-
infections (see Table 3, last column).
Discussion
To our knowledge, this is the first large-scale study that
examined the seroprevalences of HBV, HCV, HIV, and
T. pallidum among blood donors in Kyrgyzstan. A
recent study on the global prevalence of chronic HBV
infection classified Kyrgyzstan as a high-endemic coun-
try, with a prevalence of HBsAg of around 10% [1], but
the prevalence estimate in that study was based on a
single study from 1992 conducted in only one province
[9]. It appears that no other estimates for HBV sero-
prevalence have been published since then [17]. The
seroprevalence observed in our study was much lower
(3.6%), which would reclassify the country from high
endemicity (≥ 8%) to a country with lower intermediate
endemicity (2 – 4.99%).
Fig. 1 Prevalences of HBV, HCV, HIV, and T. pallidum, by sex and age groups
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country with a high prevalence in 2005 (> 3.5%) [2].
However, based on our estimate (3.1%; 95%CI: 3.0 –
3.3%), it would need to be reclassified into a country
with moderate prevalence (1.5 – 3.5%). There has only
been one study conducted on HCV prevalence in
Kyrgyzstan, which was reported by Hope et al. in their
review paper [17]. This study was a small-scale study
conducted among pregnant women (n = 898) in only one
province of Kyrgyzstan in 2005; the prevalence of HCV
observed in this study was lower (1.6%) than the esti-
mate from our study. Another study reported an HCV
prevalence of 4% in the general Kyrgyz population [18].
Studies from the former Soviet republics showed similar
HCV prevalence estimates, e.g., 2.8% (Lithuania, healthy
inhabitants, n = 1 528) [19]; 2.9% (Russia, medical stu-
dents, n = 173) [20]; 3% (Russia, pregnant women, n =
200) [21]; 3.2% (Kazakhstan, individuals aged between
10 and 64 years, n = 290) [22]; and 4% (Azerbaijan,
healthy adults, n not reported) [23]. However, a few
studies have reported somewhat lower prevalence esti-
mates, e.g., 1.6% (Russia, blood donors, n = 3 358) [24];
2% (Russia, blood donors, n = 150) [21]; 2.1% (Russia,
blood donors, n = 4 552) [20]; and 2.2% (Lithuania, blood
donors, n = 738) [25].
Overall, we observed a significantly decreasing trend
in HBV and HCV prevalence rates over the study years.
The relatively low and decreasing HBV and HCV preva-
lence rates could be explained by the introduction of atargeted program by the Kyrgyzstan Ministry of Health
titled “Prevention and treatment of viral hepatitis in the
Kyrgyz Republic for 2011–2015”, it includes, among
other measures, mandatory surveillance of HBV and
HCV [26], the development and implementation of goals
to prevent and control HBV and HCV, and increasing
access to treatment of HBV and HCV infections. There
is also a recommendation for giving HBV vaccination to
healthcare workers in Kyrgyzstan; however, the degree of
compliance with this recommendation has not yet been
assessed.
Despite this program, it is still important to undertake
further activities towards the prevention and control of
HBV and HCV, including surveillance of these infec-
tions, introducing HBV vaccination among high-risk
groups, increasing HBV vaccination coverage among
healthcare workers, and increasing awareness of HBV
and in particular of HCV among healthcare workers and
the general population. There are reports indicating
poor access to HCV testing and treatment in the former
Soviet republics, including Kyrgyzstan. The major reason
for poor access to HCV treatment is its high cost. The
Kyrgyz government does not fund HCV treatment and
patients thus need to pay for the treatment out of
pocket, which many cannot afford.
We observed a seroprevalence of HIV of about 0.78%,
which is almost eight times higher than the official
estimate in the general Kyrgyz population (0.1%) [10].
Moreover, we observed an increasing trend in HIV
Table 3 Associations of seropositivity and co-infections with sex, age, province of residence, and year of blood donation (results of
five multivariable logistic regression models)
AORs and 95%CIsa
Variables HBV HCV HIV T. pallidum Co-infectionsb
Sex
Male 1.63 (1.40 – 1.90) 0.85 (0.74 – 0.98) 0.65 (0.49 – 0.85) 1.09 (0.94 – 1.26) 1.64 (1.09 – 2.48)
Female ref. ref. ref. ref. ref.
Age group
< 20 years 1.02 (0.76 – 1.39) 0.84 (0.55 – 1.27) 0.83 (0.46 – 1.51) 0.80 (0.45 – 1.41) 0.84 (0.20 – 3.49)
20 – 29 years ref. ref. ref. ref. ref.
30 – 39 years 1.40 (1.24 – 1.58) 1.70 (1.46 – 1.97) 0.88 (0.65 – 1.20) 4.44 (3.75 – 5.26) 4.20 (2.72 – 6.48)
40 – 49 years 1.37 (1.17 – 1.60) 1.93 (1.62 – 2.30) 0.75 (0.49 – 1.15) 8.95 (7.54 – 10.62) 9.32 (6.07 – 14.29)
50 – 59 years 1.00 (0.78 – 1.28) 2.25 (1.82 – 2.79) 0.72 (0.41 – 1.28) 6.54 (5.26 – 8.14) 7.10 (4.13 – 12.21)
> 60 years 2.35 (1.35 – 4.09) 2.24 (1.17 – 4.27) NA 4.43 (2.15 – 9.13) 7.91 (1.87 – 33.43)
Province of residence
Bishkek (capital) ref. ref. ref. ref. ref.
Chuy province 1.00 (0.88 – 1.13) 0.96 (0.84 – 1.11) 0.73 (0.53 – 1.01) 1.07 (0.93 – 1.23) 0.92 (0.65 – 1.29)
Issyk-Kul province 0.86 (0.68 – 1.09) 0.73 (0.54 – 0.97) 1.65 (1.10 – 2.46) 1.57 (1.24 – 1.98) 0.61 (0.28 – 1.33)
Talas province 1.41 (1.05 – 1.89) 0.75 (0.47 – 1.17) 0.72 (0.29 – 1.78) 0.80 (0.50 – 1.26) NA
Naryn province 1.09 (0.86 – 1.38) 0.85 (0.77 – 1.15) 1.53 (0.97 – 2.41) 1.44 (1.12 – 1.87) 1.24 (0.67 – 2.30)
Jalal-Abad province 1.80 (1.42 – 2.28) 1.08 (0.87 – 1.92) 0.96 (0.48 – 1.89) 2.03 (1.54 – 2.68) 1.66 (0.85 – 3.24)
Osh province 1.70 (1.26 – 2.30) 1.29 (1.07 – 2.32) 0.69 (0.26 – 1.89) 1.54 (1.04 – 2.27) 2.19 (1.05 – 4.59)
Batken province 2.31 (1.71 – 3.13) 0.71 (0.40 – 1.26) 1.42 (0.62 – 3.24) 1.38 (0.89 – 2.16) 0.96 (0.30 – 3.08)
Year of blood donation
2013 ref. ref. ref. ref. ref.
2014 0.95 (0.84 – 1.08) 0.72 (0.62 – 0.84) 5.22 (3.48 – 7.83) 0.86 (0.74 – 1.00) 0.96 (0.66 – 1.41)
2015 0.79 (0.69 – 0.90) 0.78 (0.67 – 0.90) 2.71 (1.74 – 4.20) 1.00 (0.86 – 1.16) 1.25 (0.871.79)
NA not assessed
aAdjusted for all variables in the table
bIn total, 180 (0.48%) blood donors were positive for multiple infections (see Fig. 2)
Table 4 Co-infection rates of HBV, HCV, HIV, and T. palliduma
Co-infection rates Total positive (n) % positive
HBV with HCV 39 2.6
HCV with HBV 39 3.6
HBV with HIV 5 0.34
HIV with HBV 5 1.9
HBV with T. pallidum 69 4.6
T. pallidum with HBV 69 6.0
HCV with HIV 13 1.2
HIV with HCV 13 4.9
HCV with T. pallidum 56 5.2
T. pallidum with HCV 56 4.9
HIV with T. pallidum 10 3.8
T. pallidum with HIV 10 0.87
a Co-infection rates were calculated twice for each infection combination with
the corresponding denominators; i.e., of all HBV-infected individuals, 2.6% had
HCV co-infection, but of all HCV-individuals, 3.6% were co-infected with HBV
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are alarming and may indicate that HIV infection might
shift from high-risk groups such as intravenous drug
users or sex workers to the general population, and that
sexual transmission may become a more frequent route
of HIV transmission. This is already reflected in statis-
tics: around 58% of HIV transmission is attributed to
injecting drug use, followed by heterosexual transmis-
sion (32%, n = 5 113) [27]. Thus, community-basedTable 5 Effects of co-infection on the respective
seropositivities*
HCV HIV T. pallidum
HBV 0.89 (0.64 – 1.23)
P = 0.48
0.48 (0.20 – 1.17)
P = 0.11
1.46 (1.14 – 1.88)
P = 0.003
HCV - 1.83 (1.04 – 3.20)
P = 0.04
1.40 (1.06 – 1.85)
P = 0.02
HIV - - 1.45 (0.76 – 2.76)
P = 0.26
* Values correspond to sex- and age-adjusted ORs (95%CIs) and P-value
Fig. 2 Venn diagram showing overlap of HBV, HCV, HIV, and T.
pallidum seropositivity
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lated knowledge, in particular knowledge about HIV
transmission and risk factors and how to decrease sexual
risk behaviors, are needed. This may include educational
programs, such as school-based programs, counseling
sessions, or media campaigns [28].
The prevalence of T. pallidum infection in the present
study was 3.3%. This rate is much higher than the global
(0.5%) or regional estimates of syphilis (e.g., 0.2% for the
WHO European Region, 1.8% for the WHO African
Region) [3]. We are not aware of any other studies that
have examined the prevalence of syphilis in Kyrgyzstan.
The relatively high prevalence of syphilis means there is
an urgent need for the development of public health
actions towards better prevention, diagnosis, and treat-
ment of curable sexually transmitted infections (STIs).
Only a small proportion of donors (0.48%) in the total
sample were co-infected with more than one of the
pathogens studied. The co-infection rates in the present
study ranged between less than 1% (T. pallidum and
HIV) and 6% (T. pallidum and HBV). The co-infection
rates observed in our study were much lower than rates
reported from other regions; e.g., the rates of HIV/HBV
co-infection ranged between 9 and 17% in African coun-
tries in early 2000s [29]. The HIV/HBV and HIV/HCV
co-infection rates in heterosexual populations in West-
ern Europe and USA ranged between 4 – 6% and 9 –
27% in early 2000s, respectively [30]. In our study, the
risks of HBV and HCV seropositivity were almost 1.5
times higher among blood donors who were also positive
for T. pallidum. This finding is in agreement with other
studies that demonstrated that STIs increase the risk of
acquiring HIV, although the effect sizes in those studies
were much higher, the increase ranging between 2- and
8-fold [31].
In addition, we found that HIV seropositivity was 1.8
times higher among donors positive for HCV. This can
be explained by the higher risk of transmission (eithersexual, vertical, or parenteral) of these infections, which
share similar modes of transmission. Although the prob-
ability of heterosexual HCV transmission is very low
[32], the risk of transmission increases in the presence of
HIV co-infection. For example, Nowicki et al. compared
HCV RNA levels in cervicovaginal fluid of HIV/HCV
co-infected and HCV monoinfected women and found
that HCV RNA was present in one third of HIV/HCV
co-infected women; in contrast, no HCV RNA was
found among HCV monoinfected women [33]. Similar
findings were found for males [34]. HIV-1 sexual trans-
mission has been found to be higher among individuals
infected with other STIs compared to individuals with
no other STIs [35]. Another study showed that the odds
of vertical HCV transmission were almost two times
higher among women with HIV-HCV co-infection as
compared to women infected with HCV alone [36].
Since these infections share similar modes of transmis-
sion, common strategies should be used to prevent their
transmission.
Limitations of the study
Although blood donors have been used to estimate the
prevalence of selected infectious diseases such as HBV in
the general population [1], we cannot rule out the healthy
donor effect, which may result in an underestimation of
true prevalence rates [6]. As mentioned above, individuals
with a history of acute and chronic infections, chronic
noncommunicable diseases, and risk factors of blood-
transmissible infections were excluded from donating
blood. In addition, our sample included both first-time
(63%) and repeat donors (37%), and including repeat
donors may have resulted in a lower positivity rate, as
first-time donors with positive results were excluded. Fur-
thermore, the study population had higher proportions of
male and younger donors than the general population and
this was not representative of the general population.
However, we used poststratification weights to estimate
prevalence rates in order to control for sampling bias.
In case of positive serological results, confirmatory
tests (e.g., for HIV) were not performed. However, the
ELISA kit used for HIV detection was a fourth gener-
ation immunoassay and the diagnostic validity of all kits
was very high; for example, the sensitivity and specificity
of the DS-EIA-HBsAg kit are 100 and 99%, respectively
(see Table 1).
The availability of limited sociodemographic informa-
tion (sex, age, province of residence, and year of blood
donation) constitutes another limitation. For instance, it
was not possible to assess MSM, sex worker as an
occupation, and intravenous drug use as risk factors, as
these constitute exclusion criteria from blood donation
in Kyrgyzstan. Moreover, data on the level of education
or knowledge of specific infections such as HIV/AIDS
Karabaev et al. Infectious Diseases of Poverty  (2017) 6:45 Page 8 of 9are typically not collected from blood donors in
Kyrgyzstan and could not be included in the analysis.
Conclusions
In this study, we used serological results on the presence
of HBV, HCV, HIV, and T. pallidum among blood donors
in Kyrgyzstan to estimate the respective prevalences and
co-infection rates.
We observed a higher HIV prevalence than officially
reported in the general Kyrgyz adult population, while
the seroprevalences of HBV and HCV were lower than
the available estimates. Regarding HBV endemicity, the
country can thus be reclassified from high to lower
intermediate endemicity. Regarding HCV, Kyrgyzstan
can be reclassified from high to moderate endemicity.
The high HIV prevalence with a rising trend is an alarm-
ing finding and needs to be urgently addressed by local
public health authorities.
Only a small proportion of donors had co-infections.
However, the risk of seropositivity (e.g., HIV, HBV, and
HCV) increases with the presence of co-infections.
These groups need special attention to prevent the fur-
ther spread of infections and to improve therapy success
by monitoring them regularly, as they are at a higher risk
of developing adverse medication effects and severe liver
complications.
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